

Sara E Kochanny Ba

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8978780/publications.pdf>

Version: 2024-02-01

12
papers

181
citations

1684188

5
h-index

1474206

9
g-index

12
all docs

12
docs citations

12
times ranked

152
citing authors

#	ARTICLE	IF	CITATIONS
1	Development and Validation of a Decision Analytical Model for Posttreatment Surveillance for Patients With Oropharyngeal Carcinoma. <i>JAMA Network Open</i> , 2022, 5, e227240.	5.9	3
2	The use of artificial intelligence with uncertainty estimation to predict lung cancer relapse from histopathology.. <i>Journal of Clinical Oncology</i> , 2022, 40, 8549-8549.	1.6	1
3	Drug response prediction in patient-derived xenografts with data augmentation and multimodal deep learning.. <i>Journal of Clinical Oncology</i> , 2022, 40, e13572-e13572.	1.6	0
4	Nivolumab, nabpaclitaxel, and carboplatin followed by risk/response adaptive de-escalated locoregional therapy for HPV-associated oropharyngeal cancer: OPTIMA II trial.. <i>Journal of Clinical Oncology</i> , 2021, 39, 6011-6011.	1.6	17
5	Mathematical predication models to optimize post-treatment surveillance in HPV-associated oropharyngeal cancer.. <i>Journal of Clinical Oncology</i> , 2021, 39, 6027-6027.	1.6	0
6	The impact of site-specific digital histology signatures on deep learning model accuracy and bias. <i>Nature Communications</i> , 2021, 12, 4423.	12.8	111
7	Risk and response adapted de-intensified treatment for HPV-associated oropharyngeal cancer: Optima paradigm expanded experience. <i>Oral Oncology</i> , 2021, 122, 105566.	1.5	10
8	A randomized phase 2 study of temsirolimus and cetuximab versus temsirolimus alone in recurrent/metastatic, cetuximab-resistant head and neck cancer: The MAESTRO study. <i>Cancer</i> , 2020, 126, 3237-3243.	4.1	12
9	A randomized phase 2 network trial of tivantinib plus cetuximab versus cetuximab in patients with recurrent/metastatic head and neck squamous cell carcinoma. <i>Cancer</i> , 2020, 126, 2146-2152.	4.1	24
10	Machine learning guided adjuvant treatment of head and neck cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, 6567-6567.	1.6	1
11	Dose and volume de-escalation for HPV-associated oropharyngeal cancer: Long-term follow-up of the OPTIMA trial.. <i>Journal of Clinical Oncology</i> , 2020, 38, 6575-6575.	1.6	2
12	Prediction of histologic and molecular subsets of soft tissue sarcoma using deep learning.. <i>Journal of Clinical Oncology</i> , 2020, 38, e23529-e23529.	1.6	0